Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 399.5 DKK -1.03% Market Closed
Market Cap: 92.6B DKK

Genmab A/S
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genmab A/S
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Operating Income
kr7.1B
CAGR 3-Years
34%
CAGR 5-Years
22%
CAGR 10-Years
39%
Zealand Pharma A/S
CSE:ZEAL
Operating Income
-kr1.3B
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
-33%
Ascendis Pharma A/S
NASDAQ:ASND
Operating Income
-€278.8m
CAGR 3-Years
15%
CAGR 5-Years
-4%
CAGR 10-Years
-37%
B
Bavarian Nordic A/S
CSE:BAVA
Operating Income
kr1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Operating Income
-kr69.1m
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
-15%
Saniona AB
STO:SANION
Operating Income
-kr67m
CAGR 3-Years
47%
CAGR 5-Years
9%
CAGR 10-Years
N/A

Genmab A/S
Glance View

Economic Moat
Narrow
Market Cap
88.9B DKK
Industry
Biotechnology

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 551.82 DKK
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Genmab A/S's Operating Income?
Operating Income
7.1B DKK

Based on the financial report for Dec 31, 2024, Genmab A/S's Operating Income amounts to 7.1B DKK.

What is Genmab A/S's Operating Income growth rate?
Operating Income CAGR 10Y
39%

Over the last year, the Operating Income growth was 33%. The average annual Operating Income growth rates for Genmab A/S have been 34% over the past three years , 22% over the past five years , and 39% over the past ten years .

Back to Top